Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

This study is testing combination CAR-T cell therapy — a cutting-edge treatment where a patient's own immune cells are re-engineered to attack cancer cells — as a frontline treatment for multiple myeloma or plasmacytoma (cancers of plasma cells in the bone marrow). The goal is to achieve complete remission. **You may be eligible if...** - You have been diagnosed with multiple myeloma or plasmacytoma - The treatment goal for you is achieving complete remission - You have had a previous stem cell transplant (auto-SCT) and are eligible regardless of other prior treatments - You are expected to live for at least 12 weeks - You have adequate veins for the blood collection process (apheresis) - You are able to give informed consent and commit to ongoing follow-up **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have an active, uncontrolled infection - You have active HIV, hepatitis B, or hepatitis C - You are currently taking systemic (oral or IV) steroids - You have medical conditions that would prevent safe participation Talk to your doctor to see if this trial is right for you.